Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 20/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL804940 | 0.96 | GHSR (0.86) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13063902 | 0.94 | GHSR (0.82) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL804851 | 0.94 | GHSR (0.89) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12136018 | 0.92 | GHSR (0.79) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13752522 | 0.91 | GHSR (0.82) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL806105 | 0.91 | GHSR (0.93) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL804939 | 0.91 | GHSR (0.92) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13063904 | 0.90 | GHSR (0.90) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12197510 | 0.90 | GHSR (0.90) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12197518 | 0.90 | GHSR (0.90) | GHSRCYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071412-A1 | METHODS OF USING MACROCYCLIC AGONISTS OF THE GHRELIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL MOTILITY DISORDERS | FRASER GRAEME L (BE) | 2012-03-22 | — | — | US | disclosed |
| US-20090198050-A1 | Macrocyclic Modulators of the Ghrelin Receptor | TRANZYME PHARMA INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090198050-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | GHSR 1/4885CYP3A4 2928/4885CYP2D6 2748/4885 |
| US-20120071412-A1 | METHODS OF USING MACROCYCLIC AGONISTS OF THE GHRELIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL MOTILITY DISORDERS | GHSR, GIPR, GHRHR | GHSR 1/4885CYP3A4 1192/4885CYP2D6 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.